Docetaxel - BlueLink Pharmaceuticals

Drug Profile

Docetaxel - BlueLink Pharmaceuticals

Alternative Names: CRLX-301; Docetaxel nanoparticle - Cerulean Pharma

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cerulean Pharma
  • Developer BlueLink Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 20 Mar 2017 Cerulean enter into an agreement with BlueLink Pharmaceuticals to sell camptothecin (CRLX 101) and docetaxel (CRLX 301)
  • 04 Aug 2016 Phase-II clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease) in USA, Australia (IV)
  • 21 Mar 2016 Updated pharmacokinetics and safety data from a phase I/II trial in Solid tumours released by Cerulean Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top